Pfizer says bivalent booster increases antibodies for Omicron variants
LA TimesPfizer Inc. and its German vaccine partner BioNTech said their new COVID-19 booster designed to target the dominant Omicron subvariant produced more antibodies against the intended strains than did the original version of the shot. Pfizer and BioNTech plan to release additional data on the COVID-19 shots in the coming weeks to measure immune responses one month after administration of the new bivalent booster, which also targets the original coronavirus strain. “While we expect more mature immune-response data from the clinical trial of our Omicron BA.4/BA.5-adapted bivalent vaccine in the coming weeks, we are pleased to see encouraging responses just one week after vaccination in younger and older adults,” Pfizer Chief Executive Albert Bourla said in the statement. “These early data suggest that our bivalent vaccine is anticipated to provide better protection against currently circulating variants than the original vaccine, and potentially help to curb future surges in cases this winter.” The vaccine partners studied two cohorts that had been given the new vaccine: one comprised those ages 18 to 55, the other those 55 and up.